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Previous studies have shown that over-expression of nuclear respiratory factor (NRF)-1 in 
mice increases glucose transporter (GLUT)-4 and myocyte enhancer factor (MEF-) 2A 
content, but the mechanisms have not been elucidated. Because NRF-1 has a binding site on 
the mef2a gene, and MEF2A binds the glut4 gene as a MEF2A-MEF2D heterodimer, the 
aims of this study were to determine whether NRF-1 over-expression a) enhanced GLUT4 
expression indirectly via MEF2A and b) alters MEF2A-MEF2D dimer formation in C2C12 
myotubes.  
The Tet-on gene expression system was used to over-express NRF-1 in C2C12 
myotubes (C2C12-Tet-On-NRF-1) after treatment with 2 µg/ml doxycycline (Dox) for 72 h. 
Control myotubes were treated with vehicle. To assess if the effects of NRF-1 were mediated 
via MEF2A, some C2C12-Tet-On-NRF-1 myotubes were transfected with 80 pmol MEF2A-
siRNA to degrade MEF2A mRNA. NRF-1, GLUT4, MEF2A, MEF2D, δ-ALAS and α-
tubulin protein levels were assessed using immunoblotting. Chromatin immunoprecipitation 
(ChIP) assays were used to measure NRF-1 and MEF2A binding onto mef2a and glut4 genes, 
respectively. Co-immunoprecipitation assays using MEF2A or MEF2D antibody were carried 
out to assess MEF2A-MEF2D dimer formation after NRF-1 over-expression.  
Myotubes treated with 2 µg/ml Dox showed ~3-fold higher contents of NRF-1 and δ-
ALAS compared to controls. MEF2A and GLUT4 were increased 3- and 2-fold, respectively, 
in Dox-treated myotubes, but MEF2D was not changed. MEF2A-siRNA transfection 
prevented MEF2A increase while myotubes transfected with control-siRNA showed ~3 fold 
increase after Dox treatment. ChIP assays showed a 3-fold increase in NRF-1 binding to 
mef2a, and 2-fold increase in MEF2A binding to glut4 compared to controls. MEF2A and 
GLUT4 mRNAs were also increased (p<0.05) after NRF-1 over-expression. Co-IP assays 
showed 2-fold increase in MEF2A-MEF2D dimer formation in Dox-treated myotubes 
compared to controls.  
In conclusion, the study shows that NRF-1 over-expression increases GLUT4 content 














Introduction and Justification 
 
Insulin-mediated disposal of plasma glucose by skeletal muscle plays an important role in 
glucose homeostasis (8). Some studies have found that up to 90% of blood glucose is taken 
up by skeletal muscles in this manner (8; 28; 69). By binding to its receptors on muscle 
plasma membranes, insulin triggers translocation of GLUT4 transporters from intracellular 
vesicles to muscle cell membranes to facilitate glucose uptake. Inadequate secretion of 
insulin by pancreatic β-cells and/or disruption of its signalling pathway may result in 
accumulation of glucose in plasma, leading to the development of diabetes mellitus (28). 
GLUT4 also translocates to muscle cell membranes to enhance glucose uptake when skeletal 
muscles are contracting. However, under this condition, insulin secretion is inhibited and 
GLUT4 translocation occurs by an insulin-independent mechanism (48). In light of this 
finding, regular physical activity is prescribed as an intervention for improving glucose 
disposal and controlling plasma glucose levels in insulin-resistant and diabetic patients (89).  
Although the cellular mechanisms involved in the exercise-induced up-regulation of 
glucose disposal into skeletal muscle have not been fully elucidated, there is strong evidence 
that increased abundance of muscle GLUT4 that results from physical activity is an important 
contributing factor (36; 40; 41; 48; 62; 73). It is well established that GLUT4 expression in 
muscle is regulated by many transcription factors including myocyte enhancer factor-2 
(MEF-2) and GLUT4-enhancer factor (GEF) (76) (31; 33; 52; 62) which bind to their cis 
elements on the  glut4 gene (52; 68). Some studies further showed that MEF-2 transcription 












A study by Mora & Pessin (58) demonstrated that in skeletal muscle of normal rats 
MEF2A is dimerized to MEF2D. In this study, western blots of MEF2D immunoprecipitates 
from nuclear extracts showed co-immunoprecipitation with MEF2A. Co-
immunoprecipitation of MEF2D in western blots that were immunoprecipitated with MEF2A 
was also observed. This study further indicated that the MEF2A-MEF2D dimer is reduced in 
heart nuclear extracts of streptozotocin (STZ)-induced diabetic rats compared to controls 
after an electrophoretic mobility shift assay (EMSA). Although this experiment demonstrated 
increased binding activity of MEF2A-MEF2D dimers to the consensus MEF-2 
oligonucleotide of the glut4 promoter, it did not sufficiently demonstrate MEF2-DNA 
binding activity for GLUT4 expression. However, this was the first study to show that 
MEF2A-MEF2D is also associated with GLUT4 expression.  The interaction of MEF2A with 
MEF2D for GLUT4 expression was further demonstrated in a study by Knight et al (38) 
where COS 7 cells were transfected with the human GLUT4 promoter plasmid, which 
expressed firefly luciferase (hG4-Luc), and GEF plasmid in conjunction with either MEF2A, 
MEF2D or both plasmids. This study showed that luciferase expression was slightly elevated 
after co-transfection with both MEF2A and MEF2D plasmids, however luciferase expression 
was higher in cells co-transfection with GEF and MEF2A plasmids compared cells co-
transfection with GEF, MEF2A and MEF2D. Although this study indicates that MEF2A-
MEF2D dimer binds to the MEF-2 domain of the glut4 promoter, it demonstrates 
contradictory results from the Mora & Pessin (58) study, and this could be due to the 
different models that these two studies used. 
In addition to increasing GLUT4 expression, studies have shown that muscle 
contraction/exercise also up-regulates mitochondrial biogenesis and increases muscle 












transcription factors including nuclear respiratory factor (NRF)-1 (13; 16; 92; 98). In a study 
by Baar et al. (5), it was reported that when NRF-1 is over-expressed in skeletal muscle of 
mice, both mitochondrial proteins and GLUT4 levels increased. In light of this observation, 
some researchers have suggested that GLUT4 expression and mitochondrial biogenesis may 
share a common signalling pathway involving NRF-1 (5; 64). The mechanism by which 
NRF-1 regulates GLUT4 expression has also not been studied. Because the NRF-1 binding 
element is absent on the glut4 gene, it is unlikely that NRF-1 regulates glut4 gene expression 
directly; rather, it is more likely that NRF-1 regulates the gene indirectly via some 
intermediary. Support for this notion comes from studies by Wan & Moreadith (78) and 
Ramachandran et al. (71):  Wan & Moreadith (94), showed that the muscle-specific 
cytochrome c oxidase 6a (COX6aH) which does not contain an NRF-1 cis element is 
nevertheless influenced by NRF-1 over-expression.  Subsequently, Ramachandran et al. (71) 
demonstrated that NRF-1 indirectly regulates COX6aH through an 
NRF1→MEF2A→COX6aH transcriptional cascade;  i.e. NRF-1 binds to its element on the 
mef2a gene to increase MEF2A expression and MEF2A in turn regulates COX6aH 
expression.  The presence of an NRF-1 binding domain on mef2a gene, and the fact that 
GLUT4 expression is regulated by MEF-2 transcription factors support the hypothesis that 
over-expression of NRF-1 might also increase GLUT4 expression via a transcriptional 
cascade involving one or more of the MEF-2 isoforms. This hypothesis is supported by the 
observation that NRF-1 over-expression increased both MEF2A and GLUT4 levels in NRF-1 
transgenic mice (5). Having showed that exercise increases NRF-1 and GLUT4 expression 
via a mediation of coactivators such as peroxisome proliferator receptor gamma coactivator-1 
alpha (PGC-1α), they further wanted to know the specific effect of NRF-1 over-expression in 
skeletal muscle of transgenic mice. The use of transgenic mice in this study was effective in 












activation of other pathways that may have been confounding factors for this study. The 
results in this study effectively showed that NRF-1 over-expression does not only enhance 
the expression of mitochondrial proteins, but it also increases MEF2A and GLUT4 
expression. The disadvantage of mouse models however, is that does not guarantee replicate 
results in human studies, and that the formation of transgenic mouse models is rather a long 
process. The cell culture model would therefore be an ideal model to use as there are mouse 
and human myoblasts available that can be transfected with plasmids designed to over-
express NRF-1 in a short period of time.  
The primary purpose of the present study was to characterize the role that NRF-1 
plays in GLUT4 expression using a cell culture model. Specifically the study sought to find 
out if: a) NRF-1 binding to the mef2a gene is increased in response to NRF-1 over-expression 
in C2C12 myotubes, and b) the increase in MEF2A expression that is seen in response to 
NRF-1 over-expression is essential for GLUT4 up-regulation. Although GLUT4 expression 
has been shown to require MEF2A-MEF2D dimer formation (58; 59), a study by Baar et al. 
(5) showed that NRF-1 over-expression leads only to MEF2A and not MEF2D; the secondary 
purpose of this study was therefore, to assess the effect of NRF-1 over-expression on 
MEF2A-MEF2D dimer formation globally.  
 
In summary, the specific objectives of this study were to: a) determine whether NRF-1 over-
expression increases MEF2A and GLUT4 mRNA and protein levels in C2C12 myotubes, b) 
demonstrate whether silencing MEF2A expression in NRF-1 over-expressing muscle cells 
prevents the increase in GLUT4, c) verify if NRF-1 over-expression increases NRF-1 binding 












dimer formation globally and e) find out if NRF-1 over-expression alters MEF2A binding to 
































2.1. Introduction.   
This literature review discusses: a) the mechanism by which glucose is transported into 
skeletal muscle, with a major focus on the role played by GLUT4;  b) how GLUT4 
expression is regulated, with the main focus being placed on the role played by MEF2A, the 
transcription factor that is required for this expression; c) the various MEF-2 isoforms  and 
the dimers they form in order to bind to DNA; and lastly, d) the role that NRF-1 plays in the 
expression of the various MEF-2 isoforms and GLUT4. 
 
2.2. Skeletal muscle is a major site of glucose disposal.  
Skeletal muscle is the major site for glucose disposal and whole body glucose homeostasis 
(31; 36). Studies have reported that skeletal muscle accounts for up to 75-90% of plasma 
glucose disposal in the body (8; 46), a process mediated by facilitative proteins known as 
glucose transporters (GLUTs). To date, 13 distinct GLUTs have been identified in various 
body tissues (36; 47). The isoforms that are expressed in skeletal muscle include GLUT1 and 
GLUT4 (47; 84). While GLUT1 is constitutively localized on the plasma membrane of 
skeletal muscle, GLUT4 traffics between intracellular vesicles and the cell membrane (73; 
84).  In the basal state, GLUT4 is predominantly found in intracellular vesicles, but in the fed 
state, in response to insulin, or during muscle contraction, it translocates to the sarcolemma to 












2.2.1. Insulin-stimulated glucose disposal: Binding of insulin to its receptor causes 
autophosphorylation and activation of tyrosine kinase on the receptor, resulting in activation 
of downstream protein kinases, including insulin receptor substrate (IRS)-1 and 
phosphatidylinositol-3-kinase (PI3K). This signalling cascade results in the translocation and 
redistribution of GLUT4 proteins on the plasma membrane (21; 85). Studies have indicated 
that insulin resistance in skeletal muscle significantly reduces GLUT4 activation and 
translocation for glucose uptake.  Obesity and physical inactivity have been shown to be the 
main causes of insulin resistance which lead to hyperglycaemia and subsequently type 2 
diabetes mellitus (8; 19; 88; 89).   
 
2.2.2. Exercise-induced glucose disposal:  It is well established that exercise increases 
glucose transport and GLUT4 expression in an insulin-independent manner (27; 48; 73; 95). 
Various studies have demonstrated that glucose transport and GLUT4 expression increase at 
varying bouts of exercise in skeletal muscle (15; 19; 48). Glucose transport has been shown 
to immediately increase after a single bout of exercise (15; 27; 48; 75). GLUT4 expression 
has been shown to increase after at least 1 to 10 days of regular exercise training (20; 41; 42; 
46) as an adaptation response of skeletal muscle to regular or endurance exercise (6; 41). 
Although exercise has been demonstrated to increase glucose transport independent of the 
insulin-activated pathway, a study by Lund et al. (48) showed that muscle contraction and 
insulin stimulation further increased glucose transport in skeletal muscle. Exercise also 
increases glucose uptake by increasing GLUT4 protein and its translocation to the 
sarcolemma. Two main pathways that have been identified in exercise-induced glucose 
transport involve calcium calmodulin-dependent kinase (CaMK) and AMP-activated protein 












increase in cytosolic calcium (Ca
2+
) due to muscle contraction. CaMK was shown to be 
phosphorylated due to increased Ca
2+
 release in skeletal muscle (97). AMPK, a heterotrimeric 
enzyme consisting of the catalytic α-subunit and regulatory β- and γ-subunits is said to be 
activated as a result of intracellular energy changes caused by increases in the AMP-to ATP 
ratio (44; 53). Similar to CaMK, AMPK increases glucose transport by increasing GLUT4 
translocation to the sarcolemma. Both CaMK and AMPK have been shown to activate 
GLUT4 expression by targeting its transcription factors as described in the section below (51; 
53).   
 
2.3. Regulation of GLUT4 expression in skeletal muscle.  
2.3.1. Transcription factors for GLUT4 expression: The transcription factors that have been 
shown to be associated with GLUT4 expression are the GLUT4 enhancer factor (GEF), 
myocyte enhancer factor (MEF)-2, thyroid receptor α1 (TRα1) and myogenic determination 
1(MyoD) to mention a few (53; 102). Of those, MEF-2 and GEF have been extensively 
studied (33; 38; 58; 68). Studies have shown that transcriptional activation of GLUT4 is 
activated when MEF-2 and GEF bind to their respective domains on the glut4 gene (46; 66; 
68; 87) and that binding of MEF-2 is essential for transcription (46; 66; 87).  
 
2.3.2. MEF-2 transcription factor: MEF-2 belongs to the MADS-box family (MCM1 
Agamus Deficiens Serum) of transcriptional regulators (3; 11; 67; 99). These transcription 
factors were previously reported to be specifically expressed in muscle cells, hence the name,  
but have since been found to be present in non-muscle cell lines such as neuronal cells (67; 












called the MEF-2 DNA-binding domain (46; 87). Four MEF-2 isoforms (MEF2A; 2B; 2C & 
-2D) that bind as homodimers and/or heterodimers have been identified (67). These MEF-2 
isoforms have been shown to be involved in muscle development; MEF2B and MEF2D being 
expressed during myoblast proliferation whereas MEF2A and MEF2C are expressed during 
and after muscle differentiation respectively (10; 58).  
 
The MEF-2 isoforms that have been identified to be involved in GLUT4 expression are 
MEF2A, MEF2C and MEF2D (55; 58; 59; 87). A study by Michael et al. (55) indicated that 
MEF2C participates in GLUT4 expression when it is co-activated by PGC-1α, while MEF2A 
is activated by a number of kinases, including CaMK and AMPK (33; 52; 65). At the basal 
state, MEF2A is bound to class II histone deacetylases (HDACs) that repress its binding 
and/or transcriptional activity. Activation of CaMK and AMPK, which occurs during 
exercise, for example, was shown to phosphorylate HDACs which cause them to dissociate 
from MEF2A, leading to increased binding onto the glut4 gene for transcriptional activation 
(38; 58). McGee & Hargreaves (51) earlier showed that a single bout of exercise of reduces 
HDAC association with MEF-2. They later showed that AMPK phosphorylates HDAC5 
which results in its dissociation from MEF2A thus activating GLUT4 transcription (53). 
Activation of AMPK was not shown to phosphorylate HDACs, but Holmes et al. (33) also 
demonstrated AMPK phosphorylates GEF which leads to its nuclear localisation and binding 
to the glut4 gene. The role of CaMK was further showed in a study where transgenic mice 
expressing CaMKII indicated that CaMKII phosphorylates particularly HDAC4 in 
cardiomyocytes and also activates MEF-2 (100). These studies indicate a mechanism by 












GLUT4 is also regulated by the HDACs through activation and/or repression of its 
transcription factors (e.g. MEF2A and GEF).   
 
2.3.3. MEF2A and MEF2D dimers: Protein dimerization is the interaction of proteins to form 
large complexes that are required for regulation of cellular processes such as gene expression 
and signal transduction (37). Protein dimers act as switches for activation or inhibition of 
cellular processes during cell proliferation, apoptosis and transcriptional activation (2; 23; 49; 
74).   
In the basal state dimerization of transcription factors plays important roles in 
expression of genes that regulate the cell cycle, development and other biological processes 
(2). The importance of transcription factor dimerization is that they increase DNA binding 
affinity on their target genes for transcriptional activation.  Transcription factors are known to 
contain a dimerization domain located at the N-terminus which plays a role in DNA binding. 
Mutation of the dimerization domain in some transcription factors has been shown to prevent 
DNA binding (57). Transcription factor families  that undergo dimerization include the basic 
helix-loop-helix (bHLH), the signal transducers and activators of transcription (STAT) and 
the MADS-box family (81). 
The MADS-box family has a conserved 57 amino acid MADS-box domain located at 
the N-terminus, which plays a role in dimer formation (70). Dimers of the MADS-box family 
of proteins bind well to promoters and enhancers due to the dyad symmetry or reverse 
complementarity they form which enables each protein of the dimer complex to interact with 












transcription factors is the MEF-2 family that is predominantly involved in the transcription 
of muscle-specific genes (70). 
In addition to having the MADS-box for dimerization, the MEF-2 transcription 
factors have a unique sequence called the MEF-2 domain which together with the MADS-
box domain regulates dimer formation and DNA-binding.  Some studies have reported that 
mutations in the MEF-2 domain results in diminished dimerization which decreases DNA 
binding affinity. MEF-2 isoforms also form homodimers (e.g. MEF2A-MEF2A) and 
heterodimers (e.g. MEF2A-MEF2D). The MEF2A-MEF2A homodimer has been reported to 
regulate muscle differentiation (67). The MEF2A-MEF2D heterodimer has been implicated 
in GLUT4 expression in differentiated muscle cells (47; 52). However, the factors which 
regulate the formation of the dimer species under different conditions have not been studied. 
 
2.4. The role of NRF-1 in GLUT4 expression.  
Nuclear respiratory factors (NRF-1 and NRF-2) are nuclear-localised transcription factors 
that were first described to be involved in the transcription of nuclear-encoded cytochrome c, 
(13; 17; 78). They have since been found to activate the expression of other nuclear-encoded 
genes that are involved in mitochondrial transcription and replication machinery, as well as 
heme biosynthesis (17; 90). NRF-1 has been reported to activate the transcription of most 
nuclear-encoded mitochondrial genes, and NRF-2 has been demonstrated to be involved in 
the activation of nuclear genes encoding proteins required for mitochondrial DNA 













2.4.1. NRF activation and DNA binding mechanism: NRF-2 consists of five distinct subunits 
namely α, β1, β2, γ1 and γ2 subunits that form distinct DNA-complexes on tandem recognition 
sites to induce high-affinity DNA binding (26; 77). It binds a highly conserved GGAA motif 
that is common to the recognition sites found on the ETS-domain family of transcriptional 
activators that either activate or repress transcription according to the number of base pairs 
NRF-2 binds to on DNA-dinding domain (29; 80; 86; 90; 91). The C-terminus of NRF-2 
contains a transactivation domain which consists of hydrophobic residues found on the 
glutamine-containing clusters (25). NRF-2 is known to regulate the expression of 
Mitochondrial Transcription factor (TFAM) as well as Translocase of the Outer Membrane 
(TOM) complex receptors involved in mitochondrial assembly (11).   
 Apart from being a transcriptional activator for nuclear-encoded genes, NRF-1 has 
also been shown to play a role in the expression  of non-mitochondrial genes such as those 
involved in cell cycle regulation as well as myogenesis (55; 67). In this regard, NRF-1 is 
known to stimulate the expression of MEF-2 and has been implicated in GLUT4 expression 
(5; 65). 
The N-terminus has the DNA binding domain and the nuclear localisation signal 
(NLS) as well as serine residues that are phosphorylated for DNA binding and transcriptional 
activation (24; 25; 90). NRF-1 consensus region is a GC rich motif (-CGCACATGCGCA-) 














Figure 2.1: NRF-1 structure. The diagram shows NRF-1 domains, including a DNA-
binding domain that is adjacent to the nuclear localisation site (NLS). Diagram adapted from 
R. Scarpulla (79).  
 
2.4.2. NRF-1 regulates the expression of genes that lack NRF-1 binding domain: It is well 
established that NRF-1 is a transcriptional regulator of a majority of nuclear-encoded 
mitochondrial genes. However, it has also been reported that the expression of some tissue-
specific nuclear-encoded respiratory genes are regulated by NRF-1, although they lack NRF-
1 binding sites at their promoter regions (43; 94). It is thought that NRF-1 regulates these 
genes through intermediary factors that contain the NRF-1 binding site. Some of the genes 
that lack the NRF-1 binding site are cytochrome c oxidase (COX) 6a and COX 8 which are 
expressed in cardiac and skeletal muscle (71; 94). The intermediary factor for NRF-1-induced 
COX 6aH expression was demonstrated to be MEF2A by Wan & Moreadith (94). 
Ramachandran et al. (71) further showed that the mef2a gene contains an NRF-1 binding site 
at its promoter region, and that NRF-1 uses MEF2A as an intermediary for the co-ordinate 
expression of COX 6aH in cardiac and skeletal muscle. Furthermore, Ramachandran et al. 
(71) demonstrated that the mef2a promoter activity is regulated by NRF-1, and that silencing 
of NRF-1 by RNA interference significantly reduced mef2a promoter activity. This study by 












uses other transcription factors as intermediaries to co-ordinately regulate the expression of 
tissue-specific mitochondrial genes.  
 
2.4.3. Regulation of GLUT4 expression by NRF-1: A study performed by Baar et al. (5) 
revealed that during NRF-1 over-expression in mice, GLUT4 and MEF2A protein levels 
were increased. The increase in GLUT4 in this study could not be explained at the time since 
the glut4 gene does not contain binding sites for NRF-1. However, since it is now known that 
NRF-1 has a binding site on the mef2a gene and regulates MEF2A expression, it is 
reasonable to hypothesize that NRF-1 up-regulates GLUT4 indirectly via a transcriptional 
cascade involving MEF2A in the same manner as it regulates COX 6aH. The primary purpose 
of this study was therefore to explore this hypothesis; to provide evidence for or against a 
transcriptional cascade involving NRF-1MEF2AGLUT4, in order to explain the increase 
in GLUT4 expression when NRF-1 is over-expressed in cells. Given that MEF-2 
transcription factors bind the glut4 gene and regulate its expression as dimers of MEF2A and 
MEF2D, our secondary purpose was to explore the effect of NRF-1 over-expression on the 






















The primary aim of the study was to determine if NRF-1 over-expression in C2C12 myotubes 
increased MEF2A and GLUT4 protein levels via the NRF-1→MEF2A→GLUT4 cascade. 
The second aim was to determine whether NRF-1 over-expression in C2C12 myotubes 
altered MEF2A-MEF2D heterodimer formation globally. In this chapter, we describe the 
procedures used to a) culture muscle cells, b) over-express NRF-1 in C2C12 myotubes, c) 
analyse MEF2A, MEF2D and GLUT4 protein levels, d) quantify NRF-1 binding on the 
mef2a gene and MEF2A binding on the glut4 gene, and e) measure MEF2A & GLUT4 
mRNA. 
 
3.2. Source of Materials used in the study. 
Mouse myoblasts (C2C12) were obtained from the American Type Culture Collection 
(Manassas VA). Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Gibco-
BLR (Auckland, New Zealand). Fetal calf serum/fetal bovine serum (FCS/FBS), 





free) and horse serum (HS) were purchased from Highveld 
Biologicals (Lyndhurst, South Africa). Complete Roche protease inhibitors (RCPIs) were 
acquired from Roche Diagnostics (Randburg, South Africa). The MEF-2 siRNA and δ-ALAS 












primary antibodies MEF2A, NRF-1 and MEF2D were procured from Abcam (Cambridge 
UK). GLUT4 and α-Tubulin were obtained from Cell Signalling Technology, Inc. (USA). 
The polyclonal horseradish peroxidase (HRP) conjugated anti-rabbit and anti-mouse 
secondary antibodies were supplied by Dako (Carpinteria, CA). All other reagents that were 
used for western blots were purchased from Sigma Aldrich (St Louis, MO), while 
polyvinylidene diflouride (PVDF) membrane was supplied by Amersham (Buckinghamshire, 
UK). The enhanced chemiluminescent (ECL) solution was from Thermo Scientific 
(Rockford, IL) and photographic film from Kodak. Chromatin immunoprecipitation assay 
(ChIP) kit was supplied by Upstate, Millipore (Massachusetts, USA). Primers used for qPCR 
(Table 3.2) and RT-PCR (Table 3.3) were synthesised by the University of Cape Town, 
South Africa. SuperTherm Taq DNA polymerase, 10X Buffer and 25 mM Magnesium 
chloride were purchased from Medox Biotech (Chennai, India).   
 
3.3. Cell culture. 
This study used a cell culture model in which mouse myoblasts (C2C12) were the model of 
choice. All tissue culture was performed under Bioflow II Labotec laminar flow (Midrand, 
South Africa). Approximately 2 x 10
5
 C2C12 myoblasts were seeded on 10-cm collagen-
coated Petri-dishes and cultured in a Thermoforma incubator (Labotec, USA) at 37 °C. The 
myoblasts were cultured in medium (DMEM) supplemented with 10 mM creatine 
monohydrate, 100 µU/ml each of penicillin and streptomycin & 0.25 µg/ml fungizone (PSF), 
and 10% heat-inactivated FCS in an atmosphere containing 5% CO2, until they were 80-90% 
confluent. When cells were confluent, they were either passaged or differentiated into 












days. The C2C12 myotubes were used for the transfection of Tet-On plasmids to develop a 
double-stable cell line that over-expressed NRF-1. 
 
3.4. Transformation, amplification and harvesting of Tet-On plasmids. 
 In our study, NRF-1 was over expressed in C2C12 myotubes using a Tet-On gene expression 
system (Clontech, Paulo, CA). C2C12 myoblasts were transfected with two plasmids i.e. 
pTet-On and pTRE2hygNRF-1 (Fig. 3.1). The NRF-1 cDNA was previously cloned into the 
pTRE2hyg plasmid by a member of our research group. The pTet-On plasmid expresses a 
regulatory protein called reverse tetracycline transactivator (rtTA), and the response plasmid 
called pTRE2HygNRF-1 which expresses NRF-1when rtTA binds to its tetracycline response 
element (TRE) in the presence of the tetracycline derivative-doxycycline (Dox).  
 
Figure 3.1: Tet-On plasmids that were used for NRF-1 over-expression in C2C12 cells. 















3.4.1. Bacterial transformation and amplification: The Tet-On plasmids (pTet-On; 
pTRE2hyg; pTRE2hygNRF-1) were respectively amplified by transformation using E. coli 
DH5α competent cells. Fifty nanograms of the plasmids and a control empty vector, pRL-TK,  
were separately added into 100 µl of competent DH5α cells in 1.5 ml eppendorf tubes and 
gently mixed and incubated on ice for 30 minutes (min). The tubes were thereafter placed in a 
water bath at 42 °C for 50 seconds (s) to heat shock the DH5α cells and allow pores on 
bacterial membrane to open so that plasmids could be taken into bacteria (transformation).  
To retain the plasmids in bacteria the tubes were again incubated in ice for 2 min.  Nine 
hundred microlitres of Soc medium (2% bacto tryptone; 0.5% yeast extracts; 2.5mM KCl; 10 
mM MgCl2 10 mM MgSO4; 1.5% agar; 20 mM glucose) were added to the cells and 
incubated at 37 °C for 20 min.  The transformed cells were thereafter plated on SOB agar 
(2% Bacto tryptone; 0.5% yeast extracts; 2.5 mM KCl; 10 mM MgCl2 10 mM MgSO4; 1.5% 
agar) containing 100 µg/ml ampicilin using the sterilised glass rod, and incubated overnight 
at 37 °C. Following overnight incubation it was observed that the cells that contained Tet-On 
plasmids formed colonies as they were resistant to ampicilin, while the cells that contained 
the pRL-TK vector which had no ampicilin resistance did not grow.  
 
3.4.2. Bacterial Lysis and harvesting of Tet-On plasmids: The bacterial colonies that had 
taken up the Tet-On plasmids were transferred into 2 ml SOC medium that contained 100 
µg/ml ampicilin and incubated overnight at 37 °C with shaking. After overnight incubation 
1.5 ml of the SOC medium was transferred into a microfuge tube and centrifuged at 12 000 x 
g for 60 s at 4 °C. The supernatant was removed and the pellet re-suspended in 200 µl of ice-
cold Solution I [50 mM glucose; 25 mM Tris-HCl (pH8.0); 10 mM EDTA]. Four-hundred 












mixed with Solution I by inversion and kept on ice for 5 min. A 300 µl volume of Solution III 
(5 M potassium acetate; glacial acetic acid) was added to the solution and mixed by inverting 
the tube for 10 s followed by 5 min incubation on ice. The bacterial lysates were thereafter 
centrifuged at 12 000 x g for 5 min at 4° C and the supernatants transferred into new tubes. 
Equal volume of phenol/chloroform was added to each tube and mixed by vortexing, 
followed by centrifugation at 12 000 x g 4° C for 2 min. The supernatants were thereafter 
transferred into new tubes and two volumes of 100% ethanol (EtOH) was added to the 
supernatants, vortexed and allowed to stand at room temperature for 2 min for DNA 
precipitation. The solution was then centrifuged at 12 000 x g for 5 min at 4° C and the 
supernatants removed. The DNA pellet was rinsed with 1 ml of 70% EtOH at 4° C and the 
DNA precipitated by centrifugation at 12 000 x g for 5 min at 4° C. The pellet containing the 
Tet-On plasmids was thereafter air-dried, dissolved in 50 µl of sterilised distilled water and 
stored at -20° C.  
 
3.4.3. DNA quantification & verification: The purity of the plasmids was determined by 
spectrophotometry using the O.DA260/O.DA280 ratio. The DNA was considered pure when the 
O.DA260/O.DA280 ratio was 1.8 - 2.0. The concentration of the plasmids was determined using 
the following formula: 
[DNA] (µl/ml) = A260 x 50 x dilution factor 
                                 1000 
 
DNA concentration of 2.0 - 4.0 µg/ml was obtained for the Tet-On plasmids. To verify that 
the harvested plasmids were indeed Tet-On plasmids, they were digested with the Xho I 












electrophoresis (Fig. 3.2). For pTet-On which is 7.4 Kb, there were two fragments sizes of 
5.0 kb and 2.4 kb (Fig. 3.2A), which are the expected fragment sizes according to 
manufacturer’s protocol. pTRE2hyg (a plasmid whose size is 5.8 Kb) also produced the 
expected digestion fragments of sizes 3.75 kb and 1.55 kb (Fig. 3.2B). The pTRE2hygNRF-1 
plasmid produced two fragments of sizes 3.75 Kb and 1.55 Kb (Fig.3.2C). Because the NRF-
1 cDNA that was cloned into pTRE2hyg was 1.74 kb and has no Xho 1 restriction site, this 
digestion profile was also predicted. The Tet-On plasmids were thereafter stored at -20° C 
and later used for transfection into C2C12 cells. 
 
 
Figure 3.2: Agarose gel for Tet-On plasmids. A 0.7% agarose gel indicating the fragments 
produced when Tet-On plasmids were digested with the Xho I restriction enzyme and 


















3.5. Production of double-stable C2C12 Tet-On-NRF-1 cells.  
An overview of the steps involved in producing double-stable C2C12 Tet-On-NRF-1 cells is 
illustrated below (Fig. 3.3). A detailed description of the protocol for each step is provided in 
the sections that follow.  
 
Figure 3.3: Tet-On transfection and selection protocol. A schematic diagram 
demonstrating the transfection protocol of Tet-On plasmids into C2C12 myoblasts to form 
the double-stable C2C12 Tet-On-NRF-1 cell line. 
 
3.5.1. Transfection of pTet-On plasmids into C2C12: The C2C12 myoblasts were cultured in 
6-well plates containing 2 ml growth medium (DMEM; 10% FBS/FCS; 1% PSF). When the 
cells were ~80% confluent they were transfected with 10 µg of either pTet-On or pTRE2hyg 
plasmids using the Fugene HD transfection reagent (Roche Diagnostics). The pTRE2hyg 












Transfections were performed in 6-well plates using 3:2, 4:2 and 8:2 Fugene (µl) to DNA 
(µg) ratios in order to determine the ratio that induced the highest transfection efficiency.  
Transfection complexes were made by adding 10 µg of pTet-On or pTRE2hyg (control) 
plasmids into different microfuge tubes containing 15, 20, or 40 µl of Fugene HD  and 0.5 ml 
of serum-free DMEM at room temperature (20 °C). C2C12 myoblasts were washed twice 
with 1X PBS at 37 °C, and 1 ml of serum free DMEM was added to the cells. After this 
initial incubation period, 1 ml of the Fugene: DNA transfection complex was added drop by 
drop into each plate and incubated overnight at 37 °C. Following overnight incubation the 
cells were trypsinised and transferred to 10-cm culture plates containing fresh growth 
medium. 
 
 3.5.2. Selection of Neomycin-resistant clones: To select C2C12 myocytes that had taken up 
the pTet-On, myoblasts were cultured in medium containing 500 µg/ml of G418 (neomycin 
analogue) for ~14 days. Medium was changed every 2 days. By day 14 the majority of cells 
that had been plated had died off but small clones of neomycin-resistant cells had begun to 
form at the bottom of the plate. Individual clones were isolated by trypsinisation inside 
cloning cylinders using manufacturer’s protocol (Corning Inc., Massachusetts USA). Briefly, 
cells were washed twice with warm 1X PBS and cloning cylinders were gently placed onto 
the bottom of the culture plate to surround individual clones. Administration of a small layer 
of petroleum jelly onto the bottom edge of the cylinder allowed it to form a tight seal with the 
bottom of the culture plate. Trypsin/EDTA (200 µl) was added to the cylinder-isolated clones 
and incubated for 2 min at 37 °C to lift the cells. Growth medium (300 µl) was added to 
deactivate trypsin and the medium containing cells was collected and centrifuged at 2000 x g 












suspended in 1 ml growth medium. These cells, called Tet-On C2C12 cells were amplified by 
continuous culturing in growth medium and passaging, as described earlier.  There were 
neomycin-resistant clones from C2C12 myoblasts that had been transfected using 3:2, 4:2, 
6:2 and 8:2 Fugene: plasmid ratios.  
 
3.5.3. Selection of Tet-ON C2C12 clones with high induction and low back ground:  It is 
reasonable to assume that the isolated clones contained pTet-On plasmid because the plasmid 
confers neomycin resistance. However, it was still necessary to select clones that expressed 
rtTA. For this reason, we transfected the various Tet-On C2C12 clones with pTREhyg-Luc 
(Clontech, Inc), a response plasmid which expresses lucifarase when rtTA binds to its 
tetracycline response element (TRE) in the presence of Dox (7). An assay was conducted to 
quantify the amount of luciferase that the various clones expressed in the presence or absence 
(vehicle) of Dox. Briefly, some pTet-On C2C12 myoblasts from the various clones (obtained 
from various Fugene: plasmid ratios) were cultured in  6-well plates, and upon reaching 80% 
confluence the pTRE2hyg-Luc plasmid was transfected into Tet-On C2C12 cells according to 
the Fugene HD protocol for 6-well plates; and the cells incubated at 37 °C and 5% CO2 for 6 
h in serum-free DMEM. Transfection medium was then replaced by growth medium in the 
presence or absence of 2 µg/ml Dox and clones were maintained in this medium for 48 h. 
Cells were rinsed twice with 1X cold PBS, and 900 µl of a 1X Cell Culture Lysis Reagent 
(CCLR) was added onto the cells and the lysates scraped and transferred into microfuge 
tubes, and centrifuged at 12000 x g for 2 min at room temperature. The supernatants were 
transferred into new microfuge tubes. Ten µl of the supernatants were mixed with 50 µl of 
the luciferase reagent (Luciferase assay buffer; Luciferase assay substrate) in a 96-well plate. 












luciferase produced. The pTet-On clones that were transfected with 8:2 Fugene: plasmid 
transfection ratio indicated a 7-fold high induction with a low background compared to the 
controls (Fig. 3.4).  
 
 
Figure 3.4: Luciferase activity graph for C2C12 cells transfected at various Fugene: 
plasmid ratios. C2C12-Tet-On clones transfected with pTRE2hyg-Luc plasmid were treated 
with 2 µg/ml doxycycline (Dox +) or vehicle (Dox -) for 72 h. Graph shows results from 
luciferase assay to determine clones that had effectively taken up the pTet-On plasmids. Note 
the clones that had 8:2 Fugene: plasmid transfection ratio had high luciferase activity under 
Dox and low background. This clone was selected for transfection of the second plasmid 
(pTRE2hyg-NRF-1).  
 
3.5.4. Production of double-stable C2C12-Tet-On NRF-1 cells: The C2C12 Tet-On clones 
which had high expression of luciferase and low background i.e. the clones that resulted from 
a Fugene: plasmid transfection ratio of 8:2 was thereafter cultured in 6-well plates and 
transfected with either a pTRE2hyg-NRF-1 or a Tbx3-pGL3 plasmid using Fugene: plasmid 












it does not contain hygromycin-resistance genes. After overnight transfection, the cells were 
treated with 300 µg/ml hygromycin for a period of 10 days to select the double-stable 
C2C12-Tet-On-NRF-1 cells. The hygromycin-resistant clones were isolated and amplified as 
described for C2C12 Tet-On clones. Cells that were transfected with the Tbx3-pGL3 plasmid 
did not survive.  
3.5.5. Determination of NRF-1 expression by C2C12-Tet-On NRF-1 clones: The isolated 
C2C12 Tet-On-NRF-1 clones were cultured in 10-cm culture plates until they were 80% 
confluent and thereafter differentiated into myotubes by use of 2% horse serum. The clones 
were maintained in differentiation medium until myotubes were well formed. Medium was 
changed every 2 days during the differentiation period. To determine the clones that 
expressed a high level of NRF-1 in response to 2 µg/ml Dox and a low level in the absence of 
Dox (background), differentiated myotubes were treated with 2 µg/ml Dox or equal volume 
of vehicle for 72 h and NRF-1 levels measured by western blot  (Fig. 3.5) (see section 3.6 
below). Clones with high NRF-1 expression in the presence of Dox and low background were 
amplified and used for this study. This cell line is referred to as a double-stable C2C12 Tet-
On-NRF-1 cell line. A transfection efficiency assay was not performed for this study, rather 
the results of high luciferase and NRF-1 induction with low background after Dox treatment 
of each transfection step served as an indication and an indirect measurement of transfection 













Figure 3.5: Blots showing NRF-1 expression in clones that were rejected or accepted. 
NRF-1 expression was measured in double-stable Tet-On-NRF-1 clones treated with 2 µg/ml 
doxycycline (Dox) or vehicle by immunoblotting. Clones A and B indicate rejected clones 
because NRF-1 induction was high in vehicle-treated cells (high back ground). The clone that 
was selected had low background and high NRF-1 induction in response to Dox (clone C). 
 
3.6. Measurement of the contents of selected proteins in the C2C12-Tet-On-NRF-1 
myotubes. 
The purpose of this work was to investigate the mechanisms by which NRF-1 over-
expression causes GLUT4 protein to increase in muscle cells. Therefore we assayed GLUT4, 
MEF2A and MEF2D levels in C2C12-Tet-On-NRF-1 cells that were treated with Dox or 
vehicle using western blot.  Because it is well established that NRF-1 regulates the expression 
of a number of mitochondrial proteins, we also measured δ-ALAS to validate our 
experiments (The method is described below). Alpha tubulin (α-tubulin) was used as a 















3.6.1. Cell harvesting and Protein concentration determination: C2C12-Tet-On-NRF-1 cells 
were cultured on 10 cm plates and differentiated into myotubes as described earlier. They 
were then treated with 2 µg/ml Dox for 3 days. The cells were thereafter harvested on ice by 
adding 300 µl of the radioimmunoprecipitation (RIPA) buffer [56 mM Tris-HCl, pH 7.4; 150 
mM sodium chloride (NaCl); 1mM ethylenediaminetetraacetic acid (EDTA); 0.1% sodium 
dodecyl sulphate (SDS); 10 mM sodium pyrophosphate (Na4P2O7); 20 mM sodium fluoride 
(NaF); 0.15 µM Okadaic acid; 4 mM sodium orthovanadate (Na3VO4); 1X Roche complete 
protease inhibitors (RCPI); 1% Triton-X100], and the lysates were transferred into 1.5 ml 
tubes on ice. Total protein concentrations for lysates were measured using the Bradford 
method. Briefly, 5 µl of lysates were added to 0.95 ml of the Bradford reagent [0.5% 
Coomassie G250 powder; 8.5% phosphoric acid (H3PO4); 4.7% Ethanol], mixed by 
vortexing, and incubated for 5 min. Light absorbance at 595 nm was measured by a 
spectrophotometer and the protein concentration was deduced from a standard BSA curve.  
The assay was performed in triplicates. An equal volume of the 2X Laemmli Sample Buffer 
(250 mM Tris-HCl, pH 6.8; 10% glycerol; 2% SDS; 0.01% bromophenol blue) was added to 
the remaining lysate and frozen at -87 °C.  
 
3.6.2. Western Blots: Frozen lysates were thawed on ice and 5% (v/v) of β-mercaptoethanol 
was added and boiled at 95 °C for 60 s. For GLUT4 assessment 5% (v/v) β-mercapto-ethanol 
was added but the sample was not boiled according to manufacturer’s protocol. Proteins were 
separated using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) in a 1X electrophoresis running buffer (0.25M tris base; 1.28M glycine; 1% SDS) at 
120 V for 1 h at room temperature, followed by electrotransfer from gels to PVDF 












at 30 V. The PVDF membranes were washed twice with TBS-T (Tris-buffered saline-0.1% 
Tween 20 pH 7.4) for 10 min and blocked in 5% non-fat milk in TBS-T for 60 min at room 
temperature. Membranes were incubated with primary antibodies (Table 3.1) in either 1% 
milk or 5% BSA in TBS-T overnight at 4 °C. Membranes were thereafter washed twice with 
1X TBS-T for 10 min and incubated with horseradish peroxidise-conjugated anti-rabbit or 
anti-mouse secondary antibodies diluted at 1:2500 or 1:5000 respectively in 1% milk in TBS-
T (Table 3.1) for 1 h at room temperature. After the secondary antibody incubation the 
membranes were washed twice for 5 min with TBS-T and treated for 3 min with Enhanced 
Chemiluminnescent substrate (Supersignal; West Pico), and the protein bands visualised on 
Kodak film. 
 
Table 3.1: Antibody dilutions used for each target protein in western blots 
Target 
Protein 






NRF-1 Anti-NRF-1 1: 2000 Anti-rabbit/HRP 1:8000 
Δ-ALAS Anti-δ-ALAS 1:500 Anti-mouse/HRP 1:5000 
MEF2A Anti-MEF2A 1:1000 Anti-rabbit/HRP 1:5000 
MEF-2D Anti-MEF-2D 1:1000 Anti-rabbit/HRP 1:5000 















3.7. MEF2A silencing in C2C12-Tet-On-NRF-1 myotubes.  
To ascertain whether NRF-1 over-expression increases GLUT4 expression via MEF2A, 
MEF2A-specific small interfering RNA (MEF2A-siRNA; Santa Cruz Biotechnology, Inc.) 
was used to block MEF2A expression. The siRNA degrades newly synthesised mRNA at a 
cytosolic level thus preventing mRNA translation for protein synthesis.  C2C12-Tet-On-
NRF-1 cells Myotubes were then transfected with MEF2A siRNA using the Fugene X-
tremeGene transfection reagent (Roche Diagnostics, South Africa) as follows:  
Cells were washed with 1X warm PBS and incubated with 4 ml serum-free DMEM for 20 
min before 1 ml of transfection complex was introduced drop-wise. The transfection complex 
consisted of 10 µl transfection reagent: 1 µg MEF2A siRNA in 0.9 ml of serum-free DMEM. 
The cells were thereafter maintained at 37 °C in a 5% CO2 incubator for 6 h. After the 
incubation period, the myotubes were maintained in differentiation medium containing 2 
µg/ml Dox or vehicle for 72 h, harvested and analysed by western blot. 
 
3.8. Chromatin Immunoprecipitation (ChIP) & Co-immunoprecipitation Assays. 
The ChIP assays were performed to measure the binding of NRF-1 to its binding site on the 
mef2a gene and for assessing the binding of MEF2A to the glut4 gene. C2C12-Tet-On-NRF-
1 cells were cultured as above, differentiated into myotubes and treated with 2 µg/ml Dox or 














3.8.1. Formaldehyde cross-linking and sonication: After treatment with Dox or vehicle cells 
were incubated in medium containing 1% formaldehyde at 37 °C for 10 min to cross-link 
protein-DNA and protein-protein interactions. Cross-linking was stopped by adding 0.125 M 
glycine and incubating at 37 °C for 5 min. Cells were then washed twice with cold 1X PBS 
and lysed with SDS lysis buffer (1% SDS; 10 mM EDTA; 1X RCPI; 50 mM Tris, pH8.1) on 
ice. Cell lysates were transferred to microfuge tubes and sonicated on ice using MISONIX- 
Ultrasonic Liquid Processor (XL-2000 series) sonicator set at 6 watts. We found that 10 x 15 
s bursts of sonication produced the desired DNA fragment size of 200-800 bp. Following 
sonication, lysates were centrifuged at 13 000 x g for 10 min at 4 °C, and the supernatants 
containing the cross-linked DNA-protein fragments were collected into 1.5 ml tubes. A 
Bradford assay was then performed to determine total protein concentration for each sample.  
 
3.8.2. Pre-clearing: Aliquots of the supernatant containing 150 µg of total protein were 
diluted 10-fold with the ChIP dilution buffer (0.01% DSD; 1.1% Triton X-100; 1.2 mM 
EDTA; 16.7 mM Tris-HCl, pH 8.1; 167 mM NaCl). The final volume was ~1 ml for each 
sample. Endogenous immunoglobulins in the diluted supernatant were pre-cleared using 
Protein A agarose/salmon sperm DNA (50% slurry) for 1 h with rotation at 4 °C, followed by 
centrifugation at 2000 x g for 2 min. The resulting supernatants, called input (IN) samples, 
were collected into new 1.5 ml tubes. Fifty microliters (50 µl) of IN samples were stored at -














3.8.3. Immunoprecipitation of DNA-bound NRF-1, MEF2A and MEF2D proteins: The 
remaining input sample (~950 µl) was incubated with 5 µl antibodies directed against NRF-1, 
MEF2A or MEF2D at 4 °C with rotation for 36 h. For a negative control, a no-antibody 
immunoprecipitation was performed. Thereafter the antibody-bound protein-DNA complexes 
were immunoprecipitated by adding 50% slurry of Protein A agarose/salmon sperm DNA and 
incubating at 4 °C with rotation for 4 - 6 h followed by centrifugation at 2000 x g and 4 °C 
for 2 min. The supernatant was discarded but the pellet containing DNA-bound NRF-1, 
MEF2A or MEF2D proteins (depending on the antibody used) was washed with rotation for 5 
min in 1 ml low salt (0.1% SDS; 1% TritonX-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; 
150 mM NaCl)) for 5 min and centrifuged for 2 min at 2000 x g. Immunoprecipitates were 
washed and centrifuged two more times as described above except when high-salt (0.1% 
SDS; 1% Triton X-100; 2mM EDTA; 20mM Tris-HCl, pH 8.1; 500 mM NaCl) and Lithium 
chloride [0.25 mM LiCl; 1% IGEPAL-CA630; 1% deoxycholic acid (sodium salt); 1mM 
EDTA; 10mM Tris-HCl, pH 8.1] buffers were used, respectively. Lastly, the precipitated 
complexes were washed 2X with T.E buffer (pH 8.0) for 5 min and centrifuged as above. 
Following centrifugation, 150 µl of the elution buffer [1% SDS; 0.1M sodium carbonate 
(NaHCO3)] was added to the beads, rotated for 15 min at room temperature and centrifuged. 
The eluate which contained the protein-DNA complex was saved. The beads were eluted a 
second time as described above and the eluates from the two elutions were combined to form 















3.8.4. De-crosslinking and protein digestion procedures: The IN and IP samples were reverse 
cross-linked by adding 0.2M NaCl and heating at 65 °C for 4 h. Following reverse-cross-
linking, the proteins were digested by proteinase K by incubation in a buffer containing 10 µl 
of 0.5M EDTA, 20 µl Tris-HCl (pH 6.5) and 2 µl (10 mg/ml) Proteinase K at 45 °C for 1 h. 
The resulting solution contained DNA fragments that had been co-immunoprecipitated by the 
antibodies. 
 
3.8.5. Phenol/chloroform DNA Extraction: To recover DNA from solution, equal volume of 
phenol was added to IP and IN samples and, rotated for 5 min at room temperature followed 
by centrifugation at 13 000 x g for 2 min at 4 °C. The supernatants were transferred into new 
1.5 ml tubes and an equal volume of phenol/chloroform/isoamyl (25:24:1) was added, 
vortexed for 20 s, incubated with rotation for 5 min at room temperature and the supernatants 
collected into new tubes. An equal volume of chloroform/isoamyl (24:1) was then added to 
the supernatants, vortexed for 20 s and incubated for 5 min with rotation at room temperature, 
centrifuged (13 000 x g; 4° C) for 2 min. The supernatants were again transferred into new 
tubes and 2 µl of glycogen (20 mg/ml), 30 µl of 3 M sodium acetate (pH 5.2) as well as 2.5 
volume of 100% ethanol (EtOH) were added and the mixture incubated overnight at -20 °C to 
precipitate DNA. The tubes were centrifuged at 13000 x g (4 °C) for 20 min until a pellet 
appeared. The supernatants were discarded and the DNA pellet rinsed with 500 µl of 70% 
EtOH and centrifuged again as above. The 70% EtOH was removed and the pellets air-dried 
and thereafter dissolved in 25 µl of sterilised distilled water. DNA from IP and IN samples 














3.8.6. Polymerase Chain Reaction (PCR) and Electrophoresis: PCRs were performed to 
quantify the binding of a) NRF-1 onto the mef2a gene and b) the binding of MEF2A onto the 
glut4 gene in response to the various treatments. For assessment of MEF2A binding onto the 
glut4 gene, a 25 µl mastermix consisting of 0.5 µM of forward and reverse primers (Table 2), 
0.5U Taq DNA polymerase, 2 mM magnesium chloride (MgCl2), 1X Thermo pol buffer (2.5 
µl), 2 mM deoxynucleotide triphosphates (dTNPs) and 1 µg DNA from IN and IP samples 
were used. For assessment of NRF-1 binding to the mef2a gene the composition of the 
mastermix was identical as above except that 30 pmol for forward and reverse primers were 
used instead. Thirty four (34) PCR cycles were performed in an XP cycler PCR machine 
(Bioer) under the following conditions: one cycle of denaturation at 94 °C for 5 min and 33 
cycles at 94 °C for 30 s, annealing at 63.5 °C for 30 s and the extension at 72 °C for 45 s, 
followed by final extension at 72 °C for 10 min. Separate PCRs with control primers that do 
not bind the NRF-1 binding domain on the mef2 gene or MEF-2 cis element on the glut4 gene 
were also performed as negative controls. Ten microlitres of PCR products and 5 µl of DNA 
marker were mixed with 2 µl of SYBR gold and loaded into wells of 2% agarose gels and 


















Table 3.2: Primers used for ChIP assays  
Primers Amplicon 
size (bp) 
Forward (F) & Reverse (R) Primer Sequences 
NRF-1-mef-2 (+ve) 315 F: 5’ −CCT TCC TGT GCC GGG TGA TCT− 3’ 
R: 5’ −CTA TTT TTA GGA GTC AGG CCC GG− 3’ 
NRF-1-mef-2 (-ve) 250 F: 5’ −AGT TGT GCC ACC TGT CCC A− 3’ 
R: 5’ –CAA TGT CAG CTC ACA CTC A− 3’ 
MEF-2-glut4 (+ve) 
 
268 F: 5’ −CAG GCA TGG TCT CCA CAT ACA− 3’ 
R: 5’ –GGT AAC TCC AGC AGG ATG ACA− 3’ 
MEF-2-glut4 (-ve) 
 
315 F; 5’ – CCA ACA GCT CTC AGG CAT− 3’ 
R: 5’ –CCA TTC CAC AGG CAA GCA G− 3’ 
 
3.9. mRNA Analysis. 
3.9.1. RNA Extraction: Differentiated C2C12-Tet-On-NRF-1 myotubes were incubated in 
medium containing with 2 µg/ml Dox or vehicle for 6 h. After the treatment, the medium was 
replaced by Dox-free medium and the myotubes were maintained in this medium for 0 h, 4 h 
or 12 h. Following this, cells were washed with cold 1X PBS and lysed with 400 µl of the 
lysis buffer (Roche Applied Sciences, RSA) and the lysates transferred into High Pure Filter 
tubes (Roche Applied Sciences, RSA) and centrifuged at 8 000 x g for 15 s at room 
temperature. The flow-through was discarded and 90 µl of the DNase was added to each filter 
and incubated at room temperature for 15 min. After 15 min, Buffer I was added to the filter 
and centrifuged for 15 s at 8 000 x g. The flow-through was again discarded and Buffer II 












and centrifuged at 13 000 x g for 2 min and again the flow-through discarded. Fifty µl of 
elution buffer was finally added and the filter tube centrifuged at 8000 x g for 1 min and the 
flow-through which contained RNA, was then collected into a new microfuge tubes. The 
RNA was then stored at -80 °C for later use.    
 
3.9.2. Determination of RNA concentration: Analysis of RNA concentration was performed 
in triplicates using a Nanodrop ND 1000 spectrophotometer (Nanodrop Technology). RNA 
concentration was measured by placing 1 µl of the RNA onto a nanodrop and the RNA was 
considered pure when the A260/A280 nm ratio was between 1.9 and 2.1.  
 
3.9.3. cDNA synthesis: One µg of RNA was mixed with 1 µl of oligo dT primer and made up 
to 5 µl with nuclease-free water. The mixture was then incubated at 70 °C for 5 min and 
thereafter put on ice for 5 min. The mastermix [1X reaction buffer (Promega); 0.5 mM 
deoxyribonucleotide triphosphates (dNTPs); 3.0 mM magnesium chloride (MgCl2); 20 U 
RNase inhibitor (Promega); 1X reverse transcriptase buffer (Promega)] was then added to 
synthesise cDNA from the RNA using InProm-II TM reverse transcription system (Promega 
A3800) according to the manufacturer’s protocol. The cDNA aliquots were thereafter stored 
at -20 °C.  
 
3.9.4. Real time quantitative PCR: Real Time quantitative PCR (qRT-PCR) was performed to 
measure relative GLUT4 and MEF2A mRNA using Sensimix lite kit (Quantace QT 405-05, 
USA) and a LightCycler Version 4 (Roche, Switzerland) RT-PCR machine. Nine microliters 












green as well as 0.5 μM of forward and reverse primers (Table 3.3) were used with 1 μl of 
cDNA. The assay was performed in duplicates using the following conditions: 1 cycle at 95 
°C for 15 min, followed by 35 cycles at 95 °C for 5 s, 55 °C for 3 s, and 72 °C for 15 s. A 
melting cycle was also performed at 65 °C for 15 s followed by a cooling cycle at 40 °C for 
30 s. A negative control without cDNA template was also included in every assay to assess 
background signal. The relative GLUT4 and MEF2A mRNA concentrations were determined 
based on the 2-∆∆Ct method (change in threshold cycle - Ct). Ct values for GLUT4 and 
MEF2A mRNA were normalised to values from glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). 
 
Table 3.3 cDNA Primers 
cDNA Primers Amplicon 
size (bp) 
Forward (F) & Reverse (R) Primer Sequences 
mMEF2A 187 F: 5’ –GTGTACTCAGCAATGCCGAC -3’ 
R: 5’ –AACCCTGAGATAACTGCCCTC -3’ 




















3.10. Assessment of MEF2A-MEF2D dimers.  
To quantify MEF2A-MEF2D dimer in myotubes, C2C12-Tet-On-NRF-1 cells were cultured 
in 10-cm culture dishes and differentiated as described earlier (section 3. 5. 5). Differentiated 
myotubes were treated with 2 µg/ml Dox or vehicle for 72 h and harvested. On the day of 
harvesting, the cells were cross-linked, sonicated and pre-cleared as described in Sections 
3.8.1 and 3.8.2.  The resulting IN samples were immunoprecipitated with 6 µl of either anti- 
MEF2A or anti-MEF2D antibodies as described in Section 3.8.3. To check if all MEF2A 
protein was removed from the supernatant after MEF2A immunoprecipitation, the 
supernatant (Sup) was air-dried, diluted with 1X LSB and thereafter probed with MEF2A 
antibody. A similar process was done with regard to MEF2D immunoprecipitation. The 
immunoblots in figure 3.6 indicate that all of the MEF2A and MEF2D proteins were 
immunoprecipitated from the supernatants and collected into the pellets. 
 
 
Figure 3.6: Analysis of MEF2A and MEF2D Immunoprecipitates. The western blots 














Immunoprecipitated (IP) complexes were washed and reverse cross-linked (Section 3.8.3 and 
3.8.4). Equal volume of the 1X Laemmli sample buffer as well as 5% (v/v) β-
mercaptoethanol were added to the IP samples and heated at 95° C for 30 s. The samples 
were loaded in 7.5% polyacrylamide gel, electrophoresed at 120 V for 1 h and electro-
transferred at 30 V overnight at 4° C. The membranes were washed with 1X TBS-T and 
blocked for 90 min with 5% milk in TBS-T at room temperature. This was followed by 
overnight incubation with MEF2A or MEF2D antibody in 1% TBS-T milk.  The membranes 
were washed with 1X TBS-T for 10 min and incubated with 1:5000 HRP-conjugated anti-
rabbit secondary antibody for 90 min at room temperature followed by visualising protein 
bands using the Kodak film (Amersham, USA). 
 
3.11. Statistical Analysis 
STATISTICA 10 software was used for all analyses. A student t-test was used to compare 
statistical difference between variables. The One-Way ANOVA was used to analyse 
statistical significant difference among different groups that had more than two variables. 
Where the One-Way ANOVA showed significant difference (P ≤ 0.05) the Tukey’s honestly 























The aims of the study were to: a) determine whether NRF-1 over-expression increases 
MEF2A and GLUT4 levels in skeletal muscle, and b) to examine if NRF-1 over-expression 
enhances MEF2A-MEF2D dimerization in C2C12 myotubes. Western blots were performed 
to measure MEF2A, δ-ALAS, GLUT4 and MEF2D expression following NRF-1 over-
expression. Binding assays (ChIP) were also performed to measure NRF-1 binding to mef2a 
as well MEF2A binding to the glut4 binding site. Co-immunoprecipitation (Co-IP) assays 
where C2C12-Tet-On-NRF-1 lysates were immnuoprecipitated with either MEF2A or 
MEF2D antibody and thereafter probed with either antibody to measure MEF2A-MEF2D 
dimerization in C2C12-Tet-On-NRF-1 myotubes were also performed. The schematic 














Fig 4.1: Analysis of Results. Western blots were performed to measure the protein levels 
after NRF-1 over-expression. RT-PCR was performed to analyse mRNA expression of 
MEF2A and GLUT4 at different time points. The ChIP assay was performed to measure 
NRF-1 binding to mef2a and MEF2A binding to glut4. Co-IP assay was done to MEF2A-
MEF2D dimer formation in C2C12 myotubes 
 
4.2. NRF-1 is over-expressed in C2C12-Tet-On-NRF-1 myotubes.  
To test whether NRF-1 enhances GLUT4 expression via MEF2A, Tet-On plasmids (pTet-On 
& pTRE2hyg-NRF-1) were transfected into C2C12 myoblasts to form double-stable C2C12-
Tet-On-NRF-1 to induce NRF-1 over-expression following treatment with 2 µg/ml of Dox 
for 72 h. To determine whether the double-stable C2C12-Tet-On-NRF-1 myotubes over-
expressed NRF-1, the myotubes were treated for 72 h with 2 µg/ml Dox or vehicle. The cells 
were harvested and western blots performed to measure NRF-1 expression. The result shown 
in Figure 2A indicates that NRF-1 was over-expressed ~3-fold compared to the control 












It is well established that NRF-1 over-expression induces δ-ALAS expression (17). 
Therefore, as a positive control for NRF-1 over-expression, δ-ALAS protein levels were 
measured in C2C12-Tet-On-NRF-1 myotubes treated with Dox or vehicle. The results (Fig 
4.2B) demonstrate that there was a 2.8-fold (p <0.05) increase in δ-ALAS protein levels in 
C2C12-Tet-On-NRF-1 myotubes following NRF-1 over-expression compared to control 
myotubes where NRF-1 was not over-expressed.  
 
 
Figure 4.2: NRF-1 and δ-ALAS expression in C2C12-Tet-On-NRF-1 myotubes. C2C12-
Tet-On-NRF-1 myotubes were treated for 72 h with 2 µg/ml of Dox or vehicle. Western blots 
were performed to measure NRF-1 (A) and δ-ALAS expression (B). Data presented as Means 














4.3. MEF2A but not MEF2D is up-regulated following NRF-1 over-expression.  
It is known that MEF2A and MEF2D are both involved in GLUT4 expression (38; 58). We 
therefore tested whether NRF-1 over-expression alters MEF2A and MEF2D in C2C12-Tet-
On-NRF-1 myotubes treated for 72 h with 2 µg/ml Dox compared to those treated with 
vehicle. Western blots were performed to analyse protein expression of MEF2A and MEF2D. 
The results (Fig 4.3A) show that there was ~3.1-fold (p < 0.05) increase in MEF2A compared 
to the control. There was no change in MEF2D expression following NRF-1 over-expression. 
GLUT4 levels (Fig. 4.3B) were also increased ~2-fold following NRF-1 over-expression.  
 
 
Fig. 4.3: MEF2A, MEF2D and GLUT4 expression in C2C12-Tet-On-NRF-1 myotubes. 
Protein levels of MEF2A, MEF2D and GLUT4 in C2C12-Tet-On-NRF-1 myotubes were 
analysed by western blotting after 72 h treatment with 2 µg/ml Dox or vehicle. Data 













4.4. NRF-1 over-expression increases GLUT4 via MEF2A. 
To determine whether MEF2A is necessary for GLUT4 increase by NRF-1, C2C12-Tet-On-
NRF-1 myotubes were transfected with 80 pmol of MEF2A-siRNA to silence MEF2A 
expression or control-siRNA which does not target endogenous mRNA. Thereafter 
transfected myotubes were treated with 2 µg/ml of Dox, or equivalent volumes of vehicle for 
72 h. Western blots were performed to determine the expression levels of MEF2A. The graph 
below shows that Dox-treatment increased MEF2A protein levels ~ 3-fold (p < 0.05) in 
myotubes transfected with control-siRNA compared to MEF2A-siRNA-transfected myotubes 
(Fig. 4.4A). These results indicate that MEF2A was effectively knocked out by MEF2A-
siRNA in Dox treated myotubes. Transfection with MEF2A-siRNA showed no statistical 
differences in MEF2A levels compared to wild-type C2C12. 
It is known that MEF2A is an essential transcription factor for GLUT4 expression 
(58; 87). Since our results show that NRF-1 over-expression increases MEF2A which is 
required for GLUT4 expression, we measured GLUT4 levels in C2C12-Tet-On-NRF-1 
myotubes that have been transfected with MEF2A-siRNA or control-siRNA, and treated 
them with 2 µg/ml Dox or vehicle for 72 h. Figure 4.4B shows that GLUT4 levels are 
increased ~2.1-fold (p < 0.05) in myotubes transfected with control-siRNA compared to wild-
type C2C12 and myotubes transfected with MEF2A-siRNA. This therefore indicates that 
MEF2A is required for GLUT4 regulation, and that NRF-1 increases GLUT4 levels using 

















Fig 4.4: MEF2A and GLUT4 expression in C2C12-Tet-On-NRF-1 myotubes. Myotubes 
were transfected with MEF2A- or control-siRNA, and treated with 2 µg/ml Dox or vehicle 
for 72 h. Western blot was used to measure MEF2A (A) and GLUT4 (B) expression. Data are 
presented as Means ± S.D (n = 4).  * P < 0.05. 
 
4. 5. NRF-1 over-expression increases mef2a-bound NRF-1 and glut4-bound MEF2A. 
To determine whether the increase in MEF2A and GLUT4 levels after Dox-treatment 
occurred as a result of increased interaction of NRF-1 and MEF2A transcription factors with 
the mef2a and glut4 genes, respectively, ChIP assays were performed to measure mef2a 
promoter-bound NRF-1 and glut4 promoter-bound MEF2A. Figure 4.5A demonstrates a ~ 3-
fold (p < 0.05) increase in NRF-1 binding to the mef2a promoter and a 2-fold increase (p < 
0.05) in MEF2A binding to the glut4 promoter (Fig. 4.5B) after C2C12-Tet-On NRF-1 














Figure 4.5: NRF-over-expression increases NRF-1 binding to the mef2a promoter and 
MEF2A-binding to the glut4 promoter. C2C12-Tet-On-NRF-1 myotubes were treated with 
2 µg/ml Dox or vehicle for 72 h. The cross-linked lysates were immunoprecipitated with 
NRF-1 (A) or MEF2A (B) or IgG antibody. The co-immunoprecipitated (IP) and total (IN) 
DNA were PCR amplified using appropriate promoters and electrophoresed using 2% 
agarose gel. Data Presented as Means ± S.D (n=4) * P < 0.05. 
 
4.6. NRF-1 over-expression increases MEF2A and GLUT4 mRNA. 
Quantitative RT-PCR was performed to measure MEF2A and GLUT4 mRNA following 
NRF-1 over-expression. The vehicle controls for MEF2A mRNA and GLUT4 mRNA 
represent the controls for each timeline as they all showed similar expression levels. Our 
results demonstrate that MEF2A mRNA was increased 2.5-fold (P < 0.05) 4 h post-Dox 











































Fig. 4.6: NRF-1 over-expression increases MEF2A and GLUT4 mRNA. The graphs 
indicate the increase in MEF2A and GLUT4 mRNA at 4 h and 12 h post-Dox treatment 
respectively. * indicates significance (P < 0.05) compared to corresponding control (vehicle). 
 
4.7. NRF-1 over-expression alters MEF2A-MEF2D dimer formation. 
It is well established that MEF-2 isoforms bind to the glut4 gene as MEF2A-MEF2A 
homodimer or MEF2A-MEF2D heterodimer in skeletal muscle. Since NRF-1 over-
expression increased MEF2A but not MEF2D (Fig. 4.3A) in this study, we determined 
whether this change altered MEF2A-MEF2D dimer formation. C2C12-Tet-On-NRF-1 
myotubes were treated with 2 µg/ml Dox or vehicle for 72 h and homogenized. MEF2A and 
MEF2D from 150 µl of the protein lysates were immunoprecipitated with excess (8 µl) 
MEF2A or MEF2D antibody for 36 h. The supernatants and immunoprecipitates were then 













4.7.1. Dox treatment increases MEF2A-MEF2D dimer formation: After immunoprecipitation 
with MEF2A, we analysed MEF2A and MEF2D levels in supernatants by western blot. 
Panels A and C in figure 4.7 indicate that after immunoprecipitation with MEF2A and 
MEF2D antibodies respectively, there was minimal to no MEF2A and MEF2D  proteins that 
were found in the supernatants. Panels B shows that there was co-immunoprecipitation of the 
MEF2D protein in lysates that were immunoprecipitated with the MEF2A antibody after 
NRF-1 over-expression as MEF2D protein is greatly reduced in the supernatant. Given that 
MEF2D was not changed by Dox treatment (fig. 4.3A) it is reasonable to conclude this 
treatment increased MEF2A/D dimer formation compared to vehicle treatment.  Panel D 
shows similar protein levels of MEF2A in treated and untreated lysates that were 
immunprecipitated with MEF2D. These results are not surprising as NRF-1 over-expression 
after Dox treatment increases MEF2A (fig. 4.3A). Given that MEF2A was up-regulated by 
Dox, this conclusion implies that more MEF2A was co-immunoprecipitated by the MEF2D 
















Figure 4.7: Western blots of supernatants after immunoprecipitation with MEF2A and 
MEF2D antibodies. C2C12-Tet-On-NRF-1 myotubes were treated with 2 µg/ml Dox or 
Vehicle, homogenized and immunoprecipited (IP) with excess MEF2A or MEF2D 
antibodies. Supernatants were then immunoblotted (IB) with MEF2A or MEF2D antibodies 
as indicated. Panel A shows a blot that was IP’d and IB’d with with MEF2Aindicating 
effective immuoprecipitation of MEF2A protein. Panel B shows a blot that was IP’d with 
MEFA and IB’d with MEF2D, indicating that some MEF2D protein was co-
immunopricitated together with MEF2A after Dox treatment. Panel C shows a blot that was 
IP’d and IB’d with MEF2D antibody demonstrating MEF2D immunoprecipitation was 
effective. Panel D shows a blot that was IP’d with MEF2D and IB’d with MEF2A indicating 
association of MEF2D with MEF2A. 
 
4.7.2. MEF2A and MEF2D co-immunoprecipitation increase MEF2A-MEF2D dimer 
formation after Dox treatment: When homogenates were immunoprecipitated with MEF2A 
antibody, the amount of MEF2D that was co-immunoprecipitated was increased by Dox 
treatment 2-fold relative to vehicle treatment (Figure 4.8A). Similarly, the amount of MEF2A 
that was co-immunoprecipitated with the MEF2D antibody was increased ~ 2.2-fold (Figure 
4.8B). These results show that NRF-1 over-expression in C2C12-Tet-On-NRF-1 myotubes by 













Figure 4.8: Dox treatment increases MEF2A-MEF2D dimer formation in C2C12-Tet-
On-NRF-1 myotubes. C2C12-Tet-On-NRF-1 myotubes were treated with 2 µg/ml Dox or 
vehicle for 72 h. The lysates were immunoprecipitated with MEF2A (A) or MEF2D (B) 
antibody and immunoblotted with MEF2D or MEF2A antibody. Data are presented as Mean 



























Discussion and Conclusion 
 
5. 1. Summary of findings 
The present study investigated the mechanism by which NRF-1 over-expression enhances 
GLUT4 expression by testing the hypothesis that it acts indirectly via MEF2A. Our results 
show that NRF-1 over-expression increases mRNA and protein levels of MEF2A & GLUT4, 
and protein contents of δ-ALAS but not MEF2D. Silencing of MEF2A using siRNA 
prevented the increase in GLUT4 expression following NRF-1 over-expression. ChIP assays 
indicated that NRF-1 over-expression increased NRF-1 binding to the mef2a gene, which was 
followed by increases in MEF2A mRNA and protein levels. Increased MEF2A binding onto 
the glut4 gene also resulted in augmented GLUT4 mRNA and protein. Results of the present 
study are generally consistent with those from a previous study by Baar et al. (5), who over-
expressed NRF-1 mice. However, we were only able to achieve a 3-fold induction of NRF-1 
with our NRF-1 expression system relative to controls whereas Baar et al. (5) achieved ~10-
fold increase. The relatively low induction of NRF-1 in our model, compared to Baar et al. 
(3), is possibly due to the different model systems used. Nevertheless, it is apparent that 
NRF-1 is a potent factor in both MEF2A and GLUT4 expression because our modest over-
expression of NRF-1 still led to significant increases in both proteins.  
In studies where GLUT4 mRNA and protein levels were measured at different time 
points, an increase was shown to occur between 6 h and 18 h after exercise or AMPK and/or 
CaMK activation treatments in muscle biopsies and cell culture models (40; 41; 60; 60; 101).  












periods. The time points that can be added to measure GLUT4 mRNA in this study can be up 
to 18 h, with 4 h intervals to determine if NRF-1 over-expression can further increase GLUT4 
expression. 
 
5. 2. MEF2A is a necessary intermediate in NRF-1-induced GLUT4 expression. 
A study by Ramachandran et al. (71) showed that the mef2a gene has an NRF-1 binding site 
in its promoter region. They demonstrated that over-expression of NRF-1 significantly 
increased mef2a promoter activity in C2C12 myotubes whereas silencing NRF-1 expression 
had the opposite effect. These findings have provided strong evidence that NRF-1 is a potent 
regulator of MEF2A expression. The same authors also demonstrated that NRF-1 over-
expression increases the expression of cytochrome c oxidase (COX) 6 and 8 genes which 
have MEF2A but not NRF-1 binding domains (71). Based on these results, they concluded 
that the increases in COX 6 and COX 8 expression occurred as result of a transcriptional 
cascade involving NRF-1MEF2ACOX V6/8 because the mef2a gene has an NRF-1 
binding site at its promoter region, and silencing of NRF-1 significantly reduces MEF2A 
promoter activity. Further support for this conclusion came from Wan & Moreadith (94) who 
showed that mutations at the MEF-2 site on the cox 6 gene diminished transcription of COX 
6a in myotubes, demonstrating that the MEF-2 site is required for COX 6. 
The results of the present study provide evidence that NRF-1 over-expression also 
regulates GLUT4 expression via a transcriptional cascade involving NRF-1 
MEF2AGLUT4. Lines of evidence for the cascade include:: a) increased content of 
mef2a bound NRF-1 (Figure 4.2A), b) increased MEF2A mRNA and protein (Fig. 4.6 & Fig. 












protein (Fig. 4.6 & Figure 4.3B), and e) the fact that MEF2A silencing prevented GLUT4 up-
regulation following NRF-1 over-expression (Figure 4.4B), and f) a time-line of increases in 
MEF2A and GLUT4 mRNA which are consistent with a transcriptional cascade (Fig. 4.6). 
Further evidence for a transcriptional cascade derives from a previous study by Mukwevho et 
al. ( under review) who, using a Tet-On system to over-express NRF-1 in C2C12 myotubes, 
observed that NRF-1 over-expression precedes increases in MEF2A and GLUT4 proteins by 
~6 h and 12 h, respectively.  
The mef2a gene is also known to contain the MEF-2 binding site at its promoter 
region, and had been shown to undergo transcriptional auto-regulation (14; 72). MEF-2 auto-
regulation has been shown to occur in differentiated muscle (14). With this in mind, it is 
therefore reasonable to assume that the increase in MEF2A mRNA and protein content in this 
study may have also resulted from this transcriptional auto-regulation.  
 
5.3. Does NRF-1 co-ordinate the simultaneous expression of mitochondrial biogenesis 
and GLUT4 expression in response to exercise? 
Studies have reported that exercise induces the expression of mitochondrial proteins and 
GLUT4 expression simultaneously (6; 89). However, the signalling mechanism responsible 
for synchronizing these events has not been defined. The finding from this study, showing 
that NRF-1 increases the expression of both GLUT4 and some mitochondrial proteins, 
provides evidence that NRF-1 may be part of the signalling pathway.  
 Although a number of pathways (e.g. AMPK, CaMK, calcineurin) have been shown 
to regulate GLUT4 expression via activation of GLUT4 transcription factors (e.g. MEF2A 












mechanisms by which NRF-1 regulates GLUT4 expression. Exercise has been shown to also 
increase NRF-1 protein levels but the mechanism has not been elucidated (6; 93). One of the 
exercise-induced signalling pathways that has been implicated in increased NRF-1 levels and 
transcriptional activation for mitochondrial and GLUT4 biogenesis is the AMPK pathway (6; 
9; 30; 61); however, the transcription factors that lead to increased NRF-1 in this pathway 
have not been identified. Other studies have shown that PGC-1α is a potent co-activator of 
NRF-1 and to a certain extent its expression during exercise or muscle contraction (18; 96; 
98). Co-activation of NRF-1 by PGC-1α in these studies also indicated increased expression 
of NRF-1 target genes. These studies therefore demonstrate pathways by which NRF-1 can 
be activated and further expressed; therefore it is rational to suggest that the NRF-
1→MEF2A→GLUT4 cascade can also be activated by PGC-1α. It should however, be taken 
into consideration that though PGC-1α is a potent NRF-1 co-activator, it has also been 
implicated in GLUT4 expression via MEF2C (51; 55).  The signalling pathways can therefore 
be summarised in Figure 5.1, demonstrating the pathways that may lead to synchronised 
mitochondrial biogenesis and GLUT4 expression by NRF-1.   
 
 
Figure 5.1: Possible pathways for simultaneous induction of mitochondrial biogenesis 













5.4. NRF-1 as a potential drug target.  
From the results obtained in this study, that NRF-1 over-expression increases GLUT4 in a 
cascade manner involving MEF2A, it can be suggested that NRF-1 becomes a target for drug 
intervention studies. Drug intervention studies for the treatment of metabolic diseases such as 
type 2 diabetes can also target to increase NRF-1 expression to activate the aforementioned 
transcriptional cascade for regulation of GLUT4 expression. Metmorfin and 
thiazolidinediones (e.g. rosiglitazone) are well known drug treatments for insulin resistance 
and hyperglycaemia by increasing insulin sensitivity, glucose transport and to some extent 
GLUT4 expression in insulin-responsive tissue (e.g adipose tissue and skeletal muscle) (1; 4; 
35; 39). Recent cancer studies have shown that Tamoxifen and estradiol treatment in cancer 
cells increase NRF-1 expression (34; 50). A study by Ivanova et al. (34) has indicated that 
treatment of MCF-7 cells (breast cancer cells) with 4-Hydroxytamoxifen increases NRF-1 
expression by activating and recruiting oncogenes such as cJun and cFos as well as estrogen 
receptor β (ERβ). Estradiol (E2) was shown to target and increase NRF-1 at a transcriptional 
level in MC-7 cells (50). It would therefore be of interest to determine whether Tamoxifen 
does increase NRF-1 and the possibly GLUT4 in muscle cell lines, and if so, by which 
mechanism does this increase occur.   
 
5. 5. What regulated MEF2A-MEF2D dimer formation? 
It has been reported that MEF-2 factors bind to the GLUT4 promoter as a MEF2A-MEF2D 
heterodimer (58; 59). Since MEF2A but not MEF2D content was increased by NRF-1 over-
expression, we were curious to know how MEF2A-MEF2D dimer formation was affected 












increase following NRF-1 over-expression, the MEF2A-MEF2D dimer content was 
nonetheless increased. The western blots performed to measure MEF2A and MEF2D protein 
levels after co-immunoprecipitation with MEF2A or MEF2D antibody revealed that MEF2D 
is expressed in relatively higher levels compared to MEF2A at basal conditions in 
differentiated C2C12 myotubes. This therefore made us speculate that MEF2A-MEF2D 
dimer formation for GLUT4 expression is dependent on the amount of MEF2A protein 
available. And since MEF2A appears less abundant in C2C12 myotubes compared to 
MEF2D, it is reasonable to assume that MEF2A is a limiting factor in MEF2A-MEF2D 
dimer formation. Another study that suggested that MEF2A may be a limiting factor for 
GLUT4 expression and MEF2A-MEF2D dimer formation is a study by Mora et al. (59), who 
demonstrated that MEF2A levels were lower while MEF2D content remained unchanged in 
cardiac muscle of mice with SZT-induced diabetes. Further studies need to be performed to 
demonstrate that MEF2A is indeed a limiting factor in MEF2A-MEF2D dimer formation.  
 
5.6. Contribution of other MEF2 isoforms in GLUT4 expression. 
Many authors have reported that GLUT4 expression is regulated by the MEF2A-MEF2D 
heterodimer (38; 52; 58; 59). Some authors have reported that MEF2C protein also binds to 
the glut4 gene as a homodimer (38). The role of MEF2C in regulating GLUT4 expression is, 
however, controversial:  Knight et al., (38) indicated that co-activation of MEF2C by PGC-1α 
increases GLUT4 content, but Miura et al. (56) have shown otherwise. In our study we did 
not measure the content of MEF2C or investigate its associated dimers because the mef2c 
gene does not have the NRF-1 binding site, and therefore is unlikely to be changed by NRF-1 
over-expression.  MEF2A-MEF2A homodimer was not measured in this study, as literature 












87). However, it would be of interest, to perform an experiment to determine the binding 
affinity of MEF2A-MEF2A and MEF2A-MEF2D dimer on the glut4 gene. The assay that can 
perhaps demonstrate the binding affinity of these dimers would be EMSA where the MEF2A 
antibody or both MEF2A and MEF2D antibodies are separately incubated with a radiolabeled 
MEF-2 consensus double stranded oligonucleotide that matches the MEF-2 binding site on 
the glut4 gene. The MEF-2 dimers that display a supershift in EMSA will indicate the MEF-2 
dimer that has a higher binding affinity on the MEF-2 site found on the glut4 gene.    
 
5. 7. Summary and future experiments. 
Firstly, we have shown that NRF-1 over-expression increases GLUT4 levels via a 
transcriptional cascade involving NRF-1→MEF2A→GLUT4. Secondly, we have provided 
evidence suggesting that MEF2A content is one of the factors that limit MEF2A-MEF2D 
formation in C2C12 myotubes.  
 This study has demonstrated a crucial mechanism by which NRF-1 increases GLUT4 
expression. And though NRF-1 acts via MEF2A for GLUT4 upregulation, MEF2A does not 
singularly increase GLUT4 expression, but rather requires GEF for activation of GLUT4 
expression (33; 38; 87). A study by Knight et al. (38) reported that GEF and MEF2A form a 
protein-protein complex for GLUT4 expression. Another study by Sparling et al. (83) 
demonstrated that MEF2A physically interacts with GEF to increase its binding affinity to 
Domain I on the glut4 gene. It is therefore suggested that future work for the current study 
include immuprecipitation assays where C2C12-Tet-On-NRF-1 lysates be 












antibody to determine if NRF-1 over-expression also increases MEF2A-GEF protein 
interaction.  
Because artificial methods of increasing NRF-1 in muscle have indicated that NRF-1 
increases GLUT4 content and improves glucose clearance capacity (5) (and current study), 
further work needs to be conducted to investigate natural methods such as exercise or 
phytochemicals of increasing NRF-1 in skeletal muscle in vivo as mentioned ealier in the 
discussion. These methods might find value in the treatment of insulin resistance and type II 
diabetes mellitus.  
Future work should also investigate the effects of NRF-1 over-expression on MEF2A-
MEF2D binding to the glut4 gene.  We were unable to perform this assay because we did not 
have the necessary technology. The limitation of the ChIP assay in this study is that it 
primarily showed a global increase in MEF2A-MEF2D dimerization following NRF-1 over-
expression. The assays used for this study were however, unable to demonstrate increased 
MEF2A-MEF2D binding on the MEF-2 binding site of the glut4 promoter. As previously 
mentioned, EMSA will be a preferable assay that can be performed for future work to 
demonstrate increased MEF2A-MEF2D dimer formation on the glut4 gene after NRF-1 over-
expression. The assay will not only explicitly demonstrate MEF2A-MEF2D dimer formation 
on the glut4 promoter which the ChIP assay could not achieve, but it will also measure the 
migration pattern of MEF2A-MEF2D complex on the glut4 gene between Dox treated and 
control groups thus indicating the binding affinity of the dimer complex on the glut4 
promoter.  Measuring glucose uptake after NRF-1 over-expression will also be further 
evidence that NRF-1-induced GLUT4 expression also results in increased glucose uptake. 
The factors that influence dimer formation between the various MEF-2 proteins also merit 
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